Article Text

other Versions

PDF
Longitudinal effect following initiation of highly active antiretroviral therapy (HAART) on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso
  1. Nicolas Nagot (n_nagot{at}hotmail.com)
  1. Université Montpellier 1, France
    1. Abdoulaye Ouedraogo
    1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
      1. Helen A Weiss
      1. London School of Hygiene and Tropical Medicine, London, United Kingdom
        1. Issouf Konate
        1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
          1. Anselme Sanon
          1. Centre Muraz, Bobo-Dioulasso, Burkina Faso, Burkina Faso
            1. Marie-Christine Defer
            1. Centre Muraz, Bobo-Dioulasso, Burkina Faso, Burkina Faso
              1. Adrien Sawadogo
              1. University Hospital of Bobo-Dioulasso, Burkina Faso
                1. Jean-Baptiste Andonaba
                1. University Hospital of Bobo-Dioulasso, Burkina Faso
                  1. Roselyne Vallo
                  1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
                    1. Pierre Becquart
                    1. Université Montpellier 1, France
                      1. Michel Segondy
                      1. Université Montpellier 1, France
                        1. Philippe Mayaud
                        1. London School of Hygiene and Tropical Medicine, London, United Kingdom
                          1. Philippe Van de Perre
                          1. Université Montpellier 1, France

                            Abstract

                            Background: Highly active antiretroviral therapy (HAART) could decrease HIV-1 transmissibility by reducing genital and plasma HIV-1 RNA.

                            Methods: We evaluated the effect of HAART on genital and plasma HIV-1 RNA in a cohort of 39 antiretroviral-naïve women in Burkina Faso. Cervico-vaginal lavages were collected before HAART initiation and at six visits over 28 weeks whilst on HAART. Blood samples were collected at baseline and at three and four visits for CD4 and plasma HIV-1 RNA measurements, respectively.

                            Results: Before HAART, 72% of women had detectable genital HIV-1 RNA. After 18 weeks on HAART, only one woman (2.5%) had detectable plasma HIV-1 RNA, and two women (5.1%) had detectable genital HIV-1 RNA. Similar results were observed at each follow-up visit. However, 16/34 (47%) women with consistently undetectable plasma HIV-1 RNA shed HIV-1 at least once between weeks 18 and 28. In samples with detectable genital HIV-1, the mean quantity of HIV-1 RNA decreased from 3.87 prior to HAART to 3.04 log10 copies/mL at last visit (median 29 weeks, a 6.8-fold decrease in absolute number of copies/mL) (p=0.04). A significant median CD4 lymphocyte cell gain of 121 cells/µL (interquartile range, 59 to 204) was measured between pre-HAART and last visit.

                            Conclusion: These findings suggest that HAART could play a role in reducing HIV transmission in Africa, however they underscore the need to emphasize safe sex practices with HAART-taking patients.

                            • Burkina Faso
                            • HAART
                            • HIV-1
                            • genital shedding
                            • plasma viral load

                            Statistics from Altmetric.com

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.